Novartis Buys Ebewe in Oncology Generics Push

doi:10.3833/pdr.v2009i7.1130

Pharma Deals Review, Vol 2009, No 7 (2009)

Novartis Buys Ebewe in Oncology Generics Push

Taskin Ahmed

Abstract

Aiming to gain wider access to cancer drugs market, Novartis is to acquire Ebewe Pharma for €925 M (US$1.2 B). Ebewe manufactures generic injectable cancer treatments and will be assimilated into Novartis’ generics business, Sandoz.

Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.